We present a case of an 89 year old female with a rapidly growing and painless neck mass over a period of five months. No evidence of dyspnea or dysphagia was identified. Her past medical history includes a multinodular goiter diagnosed two years ago with no follow-up. Palpation revealed a large, irregular, firm, tender and painless tumor mass in the right anterior neck. She was clinically euthyroid with normal plasma level of thyroid stimulating hormones. Ultrasonography of the thyroid identified a 7.1 x 5.3 cm, ill defined hypoechoic mass arising from the right thyroid lobe. CT revealed an ill defined, low density mass in the right thyroid lobe that was adjacent to carotid artery. A total body scan did not show any other mass. The patient underwent a surgical exploration. There was a hard, intact capsule tumor of the whole right lobe of the thyroid gland, which was attached to the right carotid sheach. Subsequently, a right thyroid lobectomy was performed. The resected lobe measured 5.5 cm in the largest dimension; No lymph node metastasis was identified.
The resected specimen (4-μm) was fixed in 10% buffered formalin (Sigma Aldrich, St. Louis, MO, USA), processed and embedded in paraffin (Leica, Mannheim, Germany) using standard histological methods. Staining was visualized using an inverted microscope (TE2000-U; Nikon Corporation, Tokyo, Japan). Hematoxylin and eosin (Sigma Aldrich) staining revealed that epithelioid spindle cells with hyperchromatic, karyokinesis obviously and abundant blood sinus were seen in the tumor [ Figure  1 ]. Immunohistochemistry was performed. The monoclonal mouse anti-human vimentin (clone, V9; cat. no. AX074-YCD; dilution, 1:200; BioGenex, USA) was used for vimentin staining. The monoclonal mouse anti-human Ki 67 antigen (clone, MIB-1; cat. no. IR626; dilution, 1:200; Dako) was used for Ki 67 staining. The monoclonal mouse anti human cytokeratin (clone, AE1/AE3; cat. no. IR620; dilution, 1:100; Dako) was used for cytokeratin staining. Immunohistochemical staining was positive for CK19, CK516, p53, vimentin and Ki 67 (20%), and negative for TTF-1, TG and CD34 [ Figure 2 ]. The final diagnosis was papillary thyroid carcinoma coexisting with undifferentiated thyroid carcinoma.
Abstract
Coexistence of Papillary Thyroid Carcinoma (PTC) with Undifferentiated Thyroid Carcinoma (UTC) is extremely rare. The etiopathogenesis has not been elucidated though it may be associated with de differentiation. we report a case of an 89 yearold women with a painless mass of the right neck with 5 months. The patient underwent a lobectomy. The histology showed that the tumor was composed of epithelioid spindle cells with hyperchromatic, karyokinesis obviously and abundant blood sinus. Immunohistochemical studies demonstrated the tumor cells to be Vimentin (+), P53 (+), CK19 (+), CK516 (+), TTF-1 (-), TG (-), CD34 (-) and Ki-67 (+20 %). The patient still alive after 6 months? It is a challenging diagnosis to make due to lack of the recognition. Before making this diagnosis, it is important to strengthen awareness of the disease, especially for the elderly. And this case may be provided further evidence and images of this dedifferentiation
Introduction
Papillary thyroid carcinoma (PTC) is the commonest thyroid carcinoma worldwide [1] , while undifferentiated thyroid carcinoma (UTC) , a term we will use as a synonym for anaplastic thyroid carcinoma (ATC), ranks among the most lethal of all human malignancies, and represents nowadays less than 3% of all clinically recognized malignant thyroid neoplasms [2] . PTC, as differentiated thyroid carcinoma (DTC), has good prognosis but 5% of the patients already have distant metastasis at the diagnosis [3] . The incidence of PTC was about 83.7% in thyroid malignancies and increased 5.2% per year, according to the epidemiologic data by Cavalheiro BG et al. [4] And UTC is a rare and extremely aggressive malignancy, with the median survival of less than 6 months due to rapid progression and resistance to multimodal therapies [5] . However, coexistence of PTC with UTC is extremely rare. To the best of our knowledge, very little is known about this condition and no authoritative prognostic data exist. The present study reports the case of an 89 year old female patient diagnosed as coexistence of PTC with UTC and the relevant literature is comprehensively reviewed.
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Discussion
Thyroid cancer is the most common endocrine malignancy and its incidence goes on increasing worldwide. The majority of thyroid tumours comprise well-differentiated (papillary and follicular) thyroid carcinomas that usually carry an excellent prognosis, while a minority progress to poorly differentiated carcinoma [6] . PTC is the commonest thyroid cancer, while UTC is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. However, PTC coexisting with UTC of the thyroid is exceedingly rare. It is noteworthy that UTC may display a very polymorphic microscopic features, including spindle cells that can mimic the microscopic appearance of fibrosarcoma, leiomyosarcoma, or malignant fibrous histiocytoma. Epithelial markers can be missing in approximately 20% of cases [7] and even more often in spindle cell sarcomatoid UTCs. Vimentin is also expressed in more than 50% of UTCs [8] . PTC is typically nonaggressive tumors with the survival for stage I disease approximating 100% [9] . It shows an indolent clinical course, with localized disease commonplace, and typically do not recur or metastasize beyond local lymph nodes. Therefore, a simple thyroidectomy is of entimes curative for the lesion.UTC accounts for 1%-2% of all thyroid tumors, with the characteristics of fast progression, strong local invasion, high distant metastasis rate and so on. The tumor has a very poor prognosis, and the average survival time is approximately 6 to 8 months [10] . Multimodal therapy combining surgery, chemotherapy and radiation therapy, might achieve better results in improving survival in some patients; however, UTC has a very low cure rate even with the extremely radical treatments
In our case, the diagnosis of PTC coexisting with UTC was made on the pathological, and immunohistochemical features of the tumors, which were similar to those found in the literature [11] . Despite surgical excision, most patients die after 3 to 6 months. As to UTC, the rarity of this malignancy and the rapidity by which it grows has been a major barrier to progress in finding effective therapies. Thus, the treatment that is the current standard of care for these patients is largely palliative, and few are cured. A recent study by Antonelli A et al. [12] shows that the CLM3 (a pyrazolo [3,4-d] pyrimidine compound), as an agent with antitumor and antiangiogenic activity, is very promising in the treatment of UTC, opening the way to a future clinical evaluation. The present case study has been reported, in which the patient was still alive with no evidence of disease, with a follow-up of 6 months. As for the etiology, we agree with Eloy C et al and Evans WD [6, 11] . And this case may be provided further evidence and images of this dedifferentiation.
Conclusion
In summary, PTC coexisting with UTC of the thyroid is extremely rare. It is a challenging diagnosis to make due to lack of the recognition. Before making this diagnosis, it is important to strengthen awareness of the disease, especially for the elderly. And this case may be provided further evidence and images of this dedifferentiation. 
